Form N-CEN T. Rowe Price Corporate For: May 31
- Wall St rallies as data, RBA move lifts hope of Fed easing
- Twitter (TWTR) Jumps On Reports Musk Will Go-Ahead with Deal at Original Price
- $22 Billion in 'Unrelenting' New Short Positions Were Added Last Week - Citi
- Why is Credit Suisse in Trouble? All You Need to Know
- No Full Capitulation on Wall Street Yet - Bank of America
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
X0404 N-CEN LIVE 0000949820 XXXXXXXX 811-07353 false false false N-1A true T. ROWE PRICE CORPORATE INCOME FUND, INC. 811-07353 0000949820 549300635DE2Y4Y3E563 100 East Pratt Street Baltimore 21202 US-MD US 410-345-2000 State Street Corporation 1776 Heritage Drive Quincy 02171 617-786-3000 Custodian records for the Registrant. JPMorgan Chase Bank, London Woolgate House, Coleman Street London GB EC2P 2HD 0 44 20 7742 4000 Records related to the custody of Registrant's portfolio securities which are purchased outside the United States. The Bank of New York Mellon 103 Bellevue Parkway Wilmington 19809 800-441-9800 Fund accounting records. T. Rowe Price Services, Inc. 100 East Pratt Street Baltimore 21202 410-345-2000 Transfer, dividend disbursing, and shareholder service records. T. ROWE PRICE CORPORATE INCOME FUND, INC. 100 East Pratt Street Baltimore 21202 410-345-2000 All accounts, books, and other documents required to be maintained by the Registrant under Section 31(a) of the Investment Company Act of 1940 and the rules thereunder. N N N-1A 1 Y Bruce W. Duncan N/A N Teresa Bryce Bazemore N/A N Paul F. McBride N/A N Kellye L. Walker N/A N Robert J. Gerrard, Jr. N/A N Eric L. Veiel 003269676 Y David Oestreicher 004594569 Y Armando Capasso 007152939 100 East Pratt Street Baltimore 21202 XXXXXX Y N N N N N T. Rowe Price Investment Services, Inc. 008-25130 000008348 N/A Y N PricewaterhouseCoopers LLP 238 5493002GVO7EO8RNNS37 N N N N N N N T. Rowe Price Corporate Income Fund, Inc. S000002128 W3XKRQESCCQU5BB2H051 N 3 0 0 N/A N N Y N N JPMorgan Chase Bank 7H6GLXDRUGQFU57RNE97 N N State Street Bank and Trust Company 571474TGEMMWANRLN572 N N Other Revenue sharing split Rebate 7739903.00000000 44869.00000000 Rule 32a-4 (17 CFR 270.32a-4) Rule 12d1-1 (17 CFR 270.12d1-1) Rule 12d1-4 (17 CFR 270.12d1-4) Y Y Y N T. Rowe Price Associates, Inc. 801-00856 000105496 7HTL8AEQSEDX602FBU63 N T. Rowe Price Retirement Plan Services, Inc. 084-01917 N/A Y Y T. Rowe Price Services, Inc. 084-01079 N/A Y N N Refinitiv US Holdings Inc. 549300NF240HXJO7N016 N Markit North America, Inc. N/A N ICE Data Services 13-3668779 Tax ID N Bloomberg Finance L.P. 5493001KJTIIGC8Y1R12 N N JPMorgan Chase Bank, N.A. 7H6GLXDRUGQFU57RNE97 N Y Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1)) JPMorgan Chase Bank, London 7H6GLXDRUGQFU57RNE97 GB N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) EUROCLEAR BANK SA/NV 549300OZ46BRLZ8Y6F65 BE N Y Foreign securities depository - rule 17f-7 (17 CFR 270.17f-7) Banco Nacional De Mexico S.A. 2SFFM4FUIE05S37WFU55 MX N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) JPMorgan Chase Bank, N.A. - Sydney Branch 7H6GLXDRUGQFU57RNE97 AU N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) J.P. Morgan Bank Luxembourg S.A. 7W1GMC6J4KGLBBUSYP52 LU N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) JPMorgan Chase Bank, N.A. - New Zealand Branch 7H6GLXDRUGQFU57RNE97 NZ N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) BNP Paribas Securities Services S.C.A. - Milan Branch 549300WCGB70D06XZS54 IT N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) Skandinaviska Enskilda Banken AB, Helsinki Branch F3JS33DEI6XQ4ZBPTN86 FI N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) DBS Bank Ltd. ATUEL7OJR5057F2PV266 SG N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) State Street Bank and Trust Company 571474TGEMMWANRLN572 N N Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1)) Royal Bank of Canada ES7IP3U3RHIGC71XBU11 CA N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) Bank Handlowy w Warszawie Spolka Akcyjna XLEZHWWOI4HFQDGL4793 PL N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) Mizuho Bank, Ltd. RB0PEZSDGCO3JS6CEU02 JP N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) N T. Rowe Price Services, Inc. N/A Y N T. Rowe Price Retirement Plan Services, Inc. N/A Y Y N T. Rowe Price Associates, Inc. 7HTL8AEQSEDX602FBU63 Y N N T. Rowe Price Investment Services, Inc. 008-25130 000008348 N/A 0.00000000 Citigroup, Inc. N/A N/A 6SHGI4ZSSLCXXQSBB395 20335.00000000 JP MORGAN CHASE & CO. N/A N/A 8I5DZWZKVSZI1NUHU748 11571.00000000 Bank of America Corporation N/A N/A 9DJT3UXIJIZJI4WXO774 46.00000000 UBS Group AG N/A N/A 549300SZJ9VS8SGXAN81 CH 556.00000000 Royal Bank of Canada N/A N/A ES7IP3U3RHIGC71XBU11 CA 344.00000000 Morgan Stanley N/A N/A IGJSJL3JD5P30I6NJZ34 31382.00000000 The Goldman Sachs Group, Inc. N/A N/A 784F5XWPLTWKTBV3E584 18928.00000000 83162.00000000 Citigroup Inc. N/A N/A 6SHGI4ZSSLCXXQSBB395 143461088.00000000 BNP PARIBAS N/A N/A R0MUWSFPU8MPRO8K5P83 FR 70169521.00000000 JP MORGAN CHASE & CO. N/A N/A 8I5DZWZKVSZI1NUHU748 103605269.00000000 Morgan Stanley N/A N/A IGJSJL3JD5P30I6NJZ34 115245323.00000000 BARCLAYS PLC N/A N/A 213800LBQA1Y9L22JB70 GB 123579924.00000000 Bank of America Corporation N/A N/A 9DJT3UXIJIZJI4WXO774 103816673.00000000 Deutsche Bank Aktiengesellschaft N/A N/A 7LTWFZYICNSX8D621K86 DE 45225720.00000000 Royal Bank of Canada N/A N/A ES7IP3U3RHIGC71XBU11 CA 45933999.00000000 Wells Fargo & Company N/A N/A PBLD0EJDB5FWOLXP3B76 43011474.00000000 The Goldman Sachs Group, Inc. N/A N/A 784F5XWPLTWKTBV3E584 119148291.00000000 1292696746.00000000 N 744717332.00000000 0.00000000 N N N N false false true false false false
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Shareholders of T. Rowe Price Corporate Income Fund, Inc.
In planning and performing our audit of the financial statements of T. Rowe Price Corporate Income Fund, Inc. (the "Fund") as of and for the year ended May 31, 2022, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), we considered the Fund's internal control over financial reporting, including controls over safeguarding securities, as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements and to comply with the requirements of Form N-CEN, but not for the purpose of expressing an opinion on the effectiveness of the Fund's internal control over financial reporting. Accordingly, we do not express an opinion on the effectiveness of the Fund's internal control over financial reporting.
The management of the Fund is responsible for establishing and maintaining effective internal control over financial reporting. In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of controls. A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a company's assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
A deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis.
Our consideration of the Fund's internal control over financial reporting was for the limited purpose described in the first paragraph and would not necessarily disclose all deficiencies in internal control over financial reporting that might be material weaknesses under standards established by the PCAOB. However, we noted no deficiencies in the Fund's internal control over financial reporting and its operation, including controls over safeguarding securities, that we consider to be material weaknesses as defined above as of May 31, 2022.
This report is intended solely for the information and use of the Board of Directors of T. Rowe Price Corporate Income Fund, Inc. and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties.
/s/ PricewaterhouseCoopers LLP
July 20, 2022
PricewaterhouseCoopers LLP, 100 East Pratt Street, Suite 2600, Baltimore, Maryland 21202-1096 T: 410 783 7600, www.pwc.com/us
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nokia enhances Industrial portfolio with specialized devices for hazardous environments found in chemical, oil and gas industries
- Proactive news headlines including Core Lithium, American Rare Earths, Latin Resources and White Rock Minerals
- Intravacc Awarded US$14.6 Million NIH/NIAID Contract to Develop Intranasal Gonorrhea Vaccine
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!